MicroRNAs have been recognized as critical regulators of gene expression and might affect the risk of venous thrombosis. We aimed to identify 3 0 untranslated region (UTR) variants in coagulation genes that influence coagulation factor levels and venous thrombosis risk. The 3 0 UTR of coagulation genes were sequenced in subjects with extremely high or low plasma levels of these factors in two case-control studies. In total, 28 variants were identified. Five single nucleotide polymorphisms (SNPs) were predominantly present in one extreme level group (F2 rs1799963, F8 rs1050705 and F11 rs4253429, rs4253430 and rs1062547). Additional to F2 rs1799963, F8 rs1050705 (in men) and F11 rs4253430 were associated with an increased risk of venous thrombosis albeit confidence intervals were wide. The three F11 SNPs were in high linkage disequilibrium with functional variants rs2289252 and rs2036914. Rs1062547 and rs4253430 were associated with a significant increase of plasma FXI activity in heterozygotes and homozygotes in wild-type controls. In silico prediction revealed that these SNPs might disturb the binding sites of miR-544 and miR-513a-3p. Only miR-544 provoked a significant decrease of the luciferase activity that was not observed with a rs4253430 mutated vector. In conclusion, these results reinforce that microRNAs are candidates to play a role in haemostasis and complex disorders, such as thrombosis.
Summary
MicroRNAs have been recognized as critical regulators of gene expression and might affect the risk of venous thrombosis. We aimed to identify 3 0 untranslated region (UTR) variants in coagulation genes that influence coagulation factor levels and venous thrombosis risk. The 3 0 UTR of coagulation genes were sequenced in subjects with extremely high or low plasma levels of these factors in two case-control studies. In total, 28 variants were identified. Five single nucleotide polymorphisms (SNPs) were predominantly present in one extreme level group (F2 rs1799963, F8 rs1050705 and F11 rs4253429, rs4253430 and rs1062547). Additional to F2 rs1799963, F8 rs1050705 (in men) and F11 rs4253430 were associated with an increased risk of venous thrombosis albeit confidence intervals were wide. The three F11 SNPs were in high linkage disequilibrium with functional variants rs2289252 and rs2036914. Rs1062547 and rs4253430 were associated with a significant increase of plasma FXI activity in heterozygotes and homozygotes in wild-type controls. In silico prediction revealed that these SNPs might disturb the binding sites of miR-544 and miR-513a-3p. Only miR-544 provoked a significant decrease of the luciferase activity that was not observed with a rs4253430 mutated vector. In conclusion, these results reinforce that microRNAs are candidates to play a role in haemostasis and complex disorders, such as thrombosis.
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Venous thrombosis is a common disease with an incidence of about 1-3 cases per 1000 individuals per year in Western countries (Oger, 2000; Naess et al, 2007) . Potential major complications are death from a pulmonary embolism and development of a disabling post-thrombotic syndrome (Prandoni et al, 1996) . The susceptibility for venous thrombosis involves multiple genetic and environmental risk factors (Lijfering et al, 2010) . Genetic variation accounts for a large proportion of the risk of venous thrombosis (Souto et al, 2000) as well as a large proportion of the variation in plasma levels of coagulation factors (Vossen et al, 2004) . In recent years, many genetic variants have been identified in coagulation-related genes with an effect on coagulation factor levels or venous thrombosis (Bezemer & Rosendaal, 2007) , but most of the associations were weak or could not be replicated (Bezemer & Rosendaal, 2007) . A search for novel genetic risk factors for venous thrombosis therefore remains warranted.
In the past decade, microRNAs (miRNAs) have been recognized as critical regulators of gene expression (Carthew & Sontheimer, 2009) . MiRNAs are small non-coding conserved RNAs of about 22 nucleotides, which predominantly bind to the 3 0 untranslated region (UTR) of target genes (Bartel, 2009) . They mostly lower gene expression by decreasing mRNA translation or increasing mRNA degradation. Recent in vitro studies demonstrated that plasminogen-activator inhibitor-1 (PAI-1), fibrinogen, tissue factor and factor XI may be regulated by miRNAs, thereby supporting their role in regulating levels of haemostatic factors (Fort et al, 2010; Teruel et al, 2011; Marchand et al, 2012; Salloum-Asfar et al, 2014; Teruel-Montoya et al, 2015) . As genetic variations in the miRNA binding site of a target gene can affect the effect of miRNAs on protein regulation (Mishra et al, 2008) , we set out to study the association between miRNA target site variants in coagulation genes and venous thrombosis.
In this report on miRNA and venous thrombosis, we sequenced the 3 0 UTRs of genes coding for key haemostatic factors in subjects from two case-control studies with extreme phenotype levels of the traits of interest, i.e. high or low plasma levels of coagulation factors. Candidate variants were subsequently genotyped in the complete sample of 4485 cases and 4889 controls and the association with coagulation factor plasma levels and venous thrombosis risk was examined.
Material and methods

Study subjects
Study subjects were from two case-control studies: the Multiple Environmental and Genetic Assessment of risk factors for venous thrombosis (MEGA) study and the Leiden Thrombophilia Study (LETS). The design of the MEGA study has been previously described (Blom et al, 2005) . See Table I for the final selection of MEGA and LETS subjects per coagulation factor. Additional details are provided as Data S1.
DNA analysis and selection of variants for further genotyping in MEGA
A detailed description of blood collection and DNA isolation in MEGA and LETS has been published previously (Blom et al, 2005; Uitte de Willige et al, 2005) . For FGA, FGG and TFPI alternative transcript 3 0 UTRs were also sequenced as they did not overlap the sequence of the most abundant transcript. Additional details are provided as Data S1.
Coagulation factor assays
In the MEGA study, activity levels of prothrombin, factor VIII and factor XI were measured with a mechanical clot detection method. Activity levels of antithrombin and protein C were determined using chromogenic assays on a STA-R coagulation analyser following the instructions of the manufacturer (Diagnostica Stago, Asni eres, France). In addition, also on the STA-R analyser, fibrinogen activity was measured according to the Clauss method, and von Willebrand factor antigen levels were measured with the immunoturbidimetric method using the STA liatest kit (rabbit antihuman von Willebrand factor antibodies). An enzyme-linked immunosorbent assay (Diagnostica Stago) was used to measure factor IX antigen levels and total protein S levels in the MEGA study and TFPI-free antigen levels in LETS.
In silico prediction of miRNA binding sites
For each identified variant, the following miRNA resources were searched for a potential influence on miRNA binding: TargetScan (release 5.2: http://www.targetscan.org) (Lewis et al, 2005) , miRSVR (http://www.microrna.org/microrna/ home.do) (Betel et al, 2010) , PolymiRTS (http://compbio. uthsc.edu/ miRSNP/) (Bao et al, 2007) and Patrocles (http:// www.patrocles.org/Patrocles.htm) (Hiard et al, 2010) .
Luciferase assays
To validate in silico results, we performed transfection assays in the conventionally cultured human colon cancer cell line (HCT-116) that is deficient for Dicer (HCT-DK) (Nagalla et al, 2011) . Information on luciferase assays is provided as Data S1.
Statistical analysis
A workflow of the complete study is provided in Fig 1. Additional details on statistics are given in Data S1.
Results
Sequencing of the 3 0 UTR -regions of the nine genes in individuals with extreme low or high protein levels of specific coagulation factors (76-96 individuals per gene) led to the identification of 28 variants with a range of one to six variants per gene (Table II) . The frequency of the 28 identified single nucleotide polymorphisms (SNPs) in individuals with extreme protein values is shown in Table II . From this analysis, five common SNPs were considered candidates for further analysis as their prevalence differed between individuals with high and low levels of the coagulation factor of interest (Table II ; F2 rs1799963, F8 rs1050705, F11 rs4253429, F11 rs4253430 and F11 rs1062547). The well-known prothrombin G20210A polymorphism (F2 rs1799963) has already been genotyped in the MEGA study (Blom et al, 2005) . The remaining four SNPs had not previously been studied in relation to thrombosis and were genotyped in all 4485 cases and 4889 controls with available DNA *Activity levels are given as % of normal (100% = 1 iu/ml), except for fibrinogen (g/l). Antigen levels were measured in u/dl (factor IX, protein S) or ng/ml (tissue factor pathway inhibitor; TFPI).
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samples from the MEGA study. F11 SNPs genotypes were in Hardy-Weinberg equilibrium (HWE) in all control individuals and F8 rs1050705 genotypes were in HWE in control women with a similar minor allele frequency for F8 rs1050705-G for control men (26Á7%) and women (27Á5%). F8 rs1050705 was in partial, inverse linkage (0Á4 ≤ r 2 < 0Á5) with a F8 variant previously reported to be associated with the risk of venous thrombosis (rs1800291). Li et al (2009) previously reported on genetic variants in F11 associated with the risk of venous thrombosis, i.e., F11 rs2036914 and rs2289252. When assessing the linkage between these known variants and the variants described in this study, it became clear that the F11 variants were in partial, inverse linkage (0Á4 ≤ r 2 < 0Á5) with the previously described variants. When assessing the risk of venous thrombosis while restricting to wild-type carriers of F8 rs1800291, F8 rs1050705 was associated with an increased risk of venous thrombosis in men albeit numbers were low, leading to a very wide confidence interval (CI) [odds ratio (OR): 6Á63; 95% CI: 0Á84-52Á0]. In women, numbers were too low for meaningful estimates of the relative risk.
When restricting to wild-type carriers of the previously reported variants in linkage with the novel variants reported here, the three F11 SNPs showed a small increase in thrombosis risk ranging from 6% to 20% for heterozygous carriers and from 8% to 36% for homozygous carriers (Table III) . SNP rs4253430 and rs1062547 were in strong linkage disequilibrium (LD), with over 98% of the cases and controls carrying both variants. When we included rs4253429 and rs4253430 in one logistic model, the non-significant risk increase remained present only for rs4253430.
Subsequently, we assessed the effect of the described variants on the levels of the coagulation factors. In concordance with the increased risk of venous thrombosis, men carrying F8 rs1050705-G had 4Á5 iu/ml higher FVIII plasma levels than men carrying F8 rs1050705-A (Table IV) . In women, no clear trend in the levels of FVIII was observed for F8 rs1050705. Unfortunately, due to small numbers, we were unable to calculate the risk of venous thrombosis associated with F8 rs1050705 after adjustment for factor VIII activity.
For the three F11 SNPs, in the crude analysis, there was a clear, graded association between genotype and FXI plasma levels (Table IV) . When restricting the analysis to control subjects who were wild-type carriers of F11 rs2036914 and rs2289252, only F11 rs4253430 and rs1062547 were associated with an increase in factor XI plasma levels, i.e.: wild-type carriers: 84Á3 iu/ml, heterozygotes: 91Á9 iu/ml, homozygotes: 92Á8 iu/ml with mean differences of 7Á56 iu/ml (95% CI: 2Á38-12Á7) and 8Á50 iu/ml (95% CI: 3Á42-13Á58) for heterozygotes and homozygotes, respectively, when using wild-type carriers as a reference category. The increase in factor XI activity levels did not fully explain the increase in thrombosis risk: the logistic model revealed an OR of 1Á46 (95% CI 0Á83-2Á58) for heterozygous carriers and 1Á41 (95% CI 0Á80-2Á48) for homozygous carriers with adjustment for factor XI activity levels. Next, we searched in silico miRNAs binding sites that were eliminated or created by these SNPs using different miRNA resources. These 28 SNPs mainly predicted to delete miRNA binding sites (31 sites predicted), while only one variant was predicted to potentially create a new miRNA binding site (Table V) .
MiR-544 and miR-513a-3p are predicted to bind to the 3 0 UTR of F11 (Fig 2A) , and the two functional F11 SNPs rs4253430 and rs1062547 may destroy miRNA:F11 mRNA interaction. Using the RNAHybrid program (Rehmsmeier et al, 2004) for prediction of secondary structure and minimum free energy, we found a 20% increase in the minimum free energy value of miR-544 in a wild-type sequence compared to the mutated (rs4253430), while there was no apparent change in miR-513-3p:F11 mRNA interaction predicted for rs1062547 (Fig 2B) .
To confirm the in silico data and thus the effect of the two functional F11 SNPs, rs4253430 and rs1062547, on miRNA binding, we performed reporter assays. Co-transfection of HCT-DK cells with a luciferase reporter vector containing the 3 0 UTR of F11 and miR-544 showed a significant decrease of~35% of the luciferase activity in comparison with SCR. This inhibition was not observed when using a mutated vector with the rs4253430 polymorphism ( Fig 3A) . No effect was seen for miR-513-3p in the presence or absence of rs1062547 (Fig 3B) .
Discussion
We sequenced the 3 0 UTRs of genes coding for prothrombin (F2), factor VIII (F8), IX (F9) and XI (F11), fibrinogen (FGA, FGB and FGG), protein C (PROC), protein S (PROS1), antithrombin (SERPINC1), and TFPI using an extreme phenotype approach. Selecting individuals with extreme phenotypes increases the likelihood of detecting trait-related sequence variations (Nebert, 2000) . 
CI, confidence interval; NA, not available. *% of normal, adjusted for mean age of 48Á6 and mean von Willebrand antigen levels of 111Á1. †% of normal, adjusted for mean age of 48Á5 and sex distribution of 52Á1% women. ‡Significant compared to the reference allele (A for F8 rs1050705 and F11 rs1062547; G for F11 rs4253430) with P < 0Á05. §Significant compared to the reference allele (A for F11 rs4253429 and F11 rs1062547; G for F11 rs4253430) with P < 0Á001. ¶F11 SNPs: % of normal in non-carriers of rs2289252 and rs2036914, adjusted for mean age and sex. For F8 SNP: % of normal in non-carriers of rs1800291, adjusted for mean age and von Willebrand antigen levels.
We are, to our knowledge, the first to describe an effect of F8 rs1050705 on factor VIII plasma levels and thrombosis risk. Although F8 rs1050705 was recently described in a study by Viel et al (2007) , these authors did not evaluate these variants for an association with factor VIII plasma levels. We found increased plasma levels of FVIII, which corresponded with an increased risk of venous thrombosis for hemizygous men. Only one F8 gene variant, D1241E, has previously been associated with a modest effect on factor VIII plasma levels (Scanavini et al, 2005; Nossent et al, 2006) . In accordance with our data, the effect of D1241E on venous thrombosis risk was restricted to men (OR 0Á4; 95% CI 0Á2-0Á8) and only partly explained by the reduction in factor VIII activity levels (OR 0Á5; 95% CI 0Á2-1Á0) (Nossent et al, 2006) . The LD between D1241E and F8 rs1050705 is only moderate (0Á4 ≤ r 2 < 0Á5) (Viel et al, 2007) which might explain the difference in effect sizes for the two variants. Recently, Hinds et al (2016) reported the identification of F8 rs114209171 associated with venous thrombosis in the 23AndMe genomewide association study (GWAS). The LD between this variant and F8 rs1050705 is moderate (r 2 0Á68) and the causal variant in the locus is unknown. In their discussion, the authors of the 23andMe GWAS also refer to another SNP in F8 [rs2096362, intronic, (Tang et al, 2015) ; which was associated with factor VIII activity], which is linked to both our SNP and the one identified in their GWAS (R 2 : 0Á85 and 0Á75 respectively). The SNPs are quite distant: F8 rs1050705 is a 3 0 UTR variant whereas rs114209171 lies upstream of F8.
Six common F11 3 0 UTR variants were identified, of which three variants showed a significant difference between extreme level groups (rs4253429, rs4253430 and rs1062547).
After adjustment for the effect of well-known variants in the F11 gene, we showed that F11 rs4253430 was associated with a mild increase in the risk of venous thrombosis and with increased levels of factor XI, albeit still in normal range. In accordance with two other F11 SNPs investigated in LETS and MEGA (Li et al, 2009) , the weak association between F11 rs4253430 and the risk of venous thrombosis was partly explained by its effect on factor XI plasma activity levels. 3 0 UTR regions play a key regulatory role by different mechanisms: poly(A) site efficiency (Colgan & Manley, 1997) and also through miRNA binding (Bartel, 2009) . In silico predictions revealed that several SNPs located in the 3 0 UTR are able to modify the binding of miRNAs, whether deleting canonical binding sites or creating new binding sites. Actually, an effect of variants in miRNA target sites has been found on the risk of diseases such as Parkinson disease, colorectal cancer and childhood asthma (Sethupathy & Collins, 2008) . So, alterations of potential miRNA binding sites may have a relevant effect in the expression of the target protein by affecting plasma levels and increasing the risk of thrombosis. Indeed, we showed in this report that miR-544, that is expressed in hepatocytes (Potenza et al, 2016) , may affect F11 expression and that the presence of rs4253430 modified the interaction between miR-544 and its target. Our in vitro results clearly demonstrated that rs4253430 might mechanistically provoke an alteration in the interaction with miRNAs (Fig 2A) . At present, there are many pitfalls and limitations in the in silico predictions and it may be that additional miRNAs may regulate the expression of FXI and other haemostatic factors due to the presence of SNPs. On the other hand, massive sequencing technology is continuously discovering new mature miRNAs, thus some miRNAs not yet characterized may bind to F11 at the site of this other SNPs. Similarly, the fact that miR-513-3p did not bind to F11 3 0 UTR does not mean that another miRNA, yet to be characterized, may do so at this position. In addition, mRNA: 0 UTR variant rs1062547, along with 100 nmol/L miRNA precursor. A scrambled precursor was used as control. Luciferase activities were normalized to renilla activities. Results are represented as mean AE SD from three experiments performed in triplicate. The normalized data were expressed as changes relative to the data of the cells transfected with scrambled mimic and set as 100% *P < 0Á05. Student's t-test was calculated in mimic precursors versus SCR. CMV, cytomegalovirus; SCR, scrambled precursor; UTR, untranslated region; WT, wild-type. mechanism. Importantly, it has recently been shown that a series of plasma miRNAs are differentially expressed in patients with venous thromboembolism in comparison with healthy controls, strongly suggesting a role for miRNAs in venous thrombosis (Starikova et al, 2015; Wang et al, 2016) .
In conclusion, we identified two 3 0 UTR variants, i.e. F8 rs1050705 and F11 rs4253430 with an effect on plasma levels and venous thrombosis risk in 4485 cases and 4889 controls from the MEGA study. In vitro validations of predicted effects of miRSNPs on miRNA binding are highly recommended, but are complicated by the large number of false positives (almost 70%) generated by miRNA target prediction resources (Baek et al, 2008) . Rather than confirming current predicted effects for these two variants from miRNA resources, we recommend future studies to screen large panels of miRNAs for an effect on factor VIII or XI plasma levels.
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